Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.

ABSTRACT:

Objective

to evaluate the risk of treatment-related adverse events of different severity and different system with PD-1 or PD-L1 inhibitors.

Methods

randomized controlled trials (RCTs) that using PD-1/PD-L1 for cancer treatment were searched in the PubMed, Embase, Cochrane Library, and Web of Science from 1 January 2019 to 31 May 2021. Adverse events data were extracted from clinical trials website or original article by two authors separately. Meta-analysis was used to determine risk ratio (RR) and 95% confidence interval (95% CI) of adverse events in PD-1/PD-L1 inhibitors groups compared to that of control groups. Subgroup analyses were also performed.

Results

a total of 5,807 studies were initially identified and after exclusion, 41 studies were included in meta-an

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC8618590 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature